DowDuPont revealed as the surprise leader in global CRISPR patents; study points to potential trouble ahead – Lexology
|
DowDuPont revealed as the surprise leader in global CRISPR patents; study points to potential trouble ahead
Lexology A new study of the global CRISPR patent landscape released today provides the most detailed insight yet into how entities are seeking to protect their inventions relating to the revolutionary technology. Speaking exclusively to IAM, the report’s author … |
Xconomy |
Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost
Xconomy When it comes to spending cash on potential combinations for its cancer immunotherapy drugs, Bristol-Myers Squibb (NYSE: BMY) isn’t afraid of the b-word: billions. The New York-based pharma firm is paying Nektar Therapeutics (NASDAQ: NKTR) of San … Bristol, needing a cancer immunotherapy boost, pays shockingly steep price for Nektar drugSTAT Why Bristol-Myers Squibb just made a $1.85 billion bet on a cancer drugBusiness Insider Record-smashing $3.6 billion deal propels SF drug company in cancer immunotherapy packSan Francisco Business Times Science Magazine (blog) –Genetic Engineering & Biotechnology News –WHTC all 205 news articles » |
Technology Networks |
Lonza to Establish Cell- and Gene–Therapy Centers of Excellence to Accelerate Growth
Technology Networks Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company. This decision advances Lonza’s strategy of being one of the world’s leading, integrated, value-added … |
Technology Networks |
Lonza to Establish Cell- and Gene–Therapy Centers of Excellence to Accelerate Growth
Technology Networks Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company. This decision advances Lonza’s strategy of being one of the world’s leading, integrated, value-added … |